Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemagglutinin-strain a(h3n2)
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal, Intradermal, Subcutaneous
01
Overview
Haemagglutinin-strain A(H3N2) refers to the hemagglutinin (HA) surface glycoprotein derived from the influenza A virus subtype H3N2. HA is a class I viral fusion protein responsible for mediating viral entry into host cells by facilitating membrane fusion after endocytosis[3]. The H3N2 subtype is one of the major circulating strains causing seasonal influenza in humans and is included in annual flu vaccines[4][8]. The HA protein undergoes frequent antigenic drift through amino acid substitutions, especially at antigenic sites, allowing the virus to evade immune responses and necessitating regular updates to vaccine strains[1][5][2]. In vaccine formulations, purified or recombinant HA from specific H3N2 strains is used as an active component to induce protective immunity against circulating viruses.
- Other names
- haemagglutinin-strain a(h3n2)
02
Targets
α2,6-Sia (Alpha-2,6-linked sialic acid)
Beyond the preview
Go deeper on haemagglutinin-strain a(h3n2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemagglutinin-strain a(h3n2).